When the bacterium, Pseudomonas aeruginosa (P. aeruginosa), first colonizes the airways of an individual with cystic fibrosis (CF), there is a high chance of eradicating the bacterium using early antimicrobial treatment. However, early treatment may fail to eradicate P. aeruginosa on some occasions. Therefore, in this study we wanted to determine whether such treatment failure is associated with the emergence of mutations (i.e. changes in the DNA sequences) in certain P. aeruginosa genes.
What was your research question?
When the bacterium, Pseudomonas aeruginosa (P. aeruginosa), first colonizes the airways of an individual with cystic fibrosis (CF), there is a high chance of eradicating the bacterium using early antimicrobial treatment. However, early treatment may fail to eradicate P. aeruginosa on some occasions. Therefore, in this study we wanted to determine whether such treatment failure is associated with the emergence of mutations (i.e. changes in the DNA sequences) in certain P. aeruginosa genes.
Why is this important?
Chronic airway infections with P. aeruginosa are the most frequent co-morbidity associated with a high treatment burden and impaired quality of life for people with CF. Early antimicrobial treatment is a successful strategy to prevent or at least delay chronic P. aeruginosa infection. Investigation of P. aeruginosa recovered from treatment failures could teach us how to improve our early treatment regimens.
What did you do?
Over 10-years, we collected the first and subsequent P. aeruginosa airway isolates (pre-and post-treatment isolates) from previously negative for P. aeruginosa patients who were cared for at the CF center Hannover since the age of diagnosis. Of 54 patients who became positive for P. aeruginosa for the first time, 15 patients remained positive for P. aeruginosa after the first round of early antimicrobial treatment. A total of 34 genes that are known to
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What did you find?
We detected a total of 50 mutations in 12/34 target genes in post-treatment isolates compared to pre-treatment isolates of eleven patients. More than 60% of mutations emerged in P. aeruginosa genes that control the transport of antibiotics across the cell wall and another 20% of mutations emerged in genes that are responsible for the production of biofilms. Numerous pre-and post-treatment P. aeruginosa isolates contained mutations in a gene called lasR. lasR is a central control element of cell to cell communication and pathogenbicity of P. aeruginosa.
What does this mean and reasons for caution?
Early antimicrobial treatment selects for mutations in genes that affect biofilm formation and drug resistance (also known as pathoadaptive traits) in P. aeruginosa .These mutations are typical of chronic infections with P. aeruginosa in CF lungs.
What's next?
These results are from a single CF center and should be backed up by the investigation of early treatment P. aeruginosa isolates from other CF centers.
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